Sunday, July 6, 2025 7/6/2025

Macrophage and osteoclast specific targeting for the prevention and treatment of breast cancer bone metastasis

Award Number: K01OD026527
ORGANIZATION: OFFICE OF THE DIRECTOR, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 08/07/2018
PERIOD OF PERFORMANCE END DATE: 07/31/2023

Group Awards By:

View Award Description

Macrophage and osteoclast specific targeting for the prevention and treatment of breast cancer bone metastasis - Project Summary/Abstract: I have completed DVM, MS, and PhD degrees, a surgical residency, and am now a Post-Doctoral Research Fellow in cancer and bone genetics and biology. This K01 award will facilitate my transition into an independent position as a tenure-track clinician-scientist studying bone metastasis and primary bone tumors. My clinical and research training will benefit both human and veterinary clinicians and researchers and promote the development of essential translational and comparative collaborations. Advancement towards independence will occur by many mechanisms during this K01 award. I will obtain knowledge and skills central to this award’s research strategy and my career goals. I will continue to hone previously learned techniques but also receive training in new methods to study cancer biology and genetics, the tumor microenvironment, bone biology, and metastasis. I will receive training in essential non-laboratory research skills such as grantsmanship, scientific writing, responsible conduct of research, and mentoring. Metastatic disease is the leading cause of breast cancer-related deaths and bone metastases occur in ~75% of patients with metastasis. In bone, cancer cells secrete factors that 1) stimulate macrophages (MPs) to differentiate into osteoclasts (OCs) and 2) increase osteoclastic bone resorption (lysis), leading to bone loss, pain, and fracture. Therefore, preventing the establishment of and treating existing bone metastasis is the goal of therapy. Colony stimulating factor 1 receptor (CSF1R) regulates the expression of the transcription factor (TF) PU.1. Our preliminary data demonstrate that the CSF1R/PU.1 axis is a key regulator of 1) tumor-associated MP (TAM) function and 2) normal MP and OC differentiation and function. In addition, several TFs and genes essential for OC differentiation and function have a strong enhancer binding pattern by PU.1 resembling “superenhancers”. These enhancers are enriched for BET proteins which bind to PU.1 to regulate key osteoclastogenic TFs. The objective of this award is to 1) investigate the role of the CSF1R/PU.1 axis and 2) determine if superenhancers play a role, in breast cancer bone metastasis. Our hypothesis is that the CSF1R/PU.1 axis is essential for bone metastasis and this occurs in the context of superenhancers. We will initially assess the effects of MP-specific deletion of PU.1 on breast cancer bone metastasis and determine genes regulated by PU.1 in both primary tumor MPs and bone metastasis MPs and OCs (Aim 1). We will then evaluate if BET inhibition can reduce the development of, and growth of established, bone metastasis and determine if increasing its specificity to specifically target MPs and OCs will increase its therapeutic efficacy (Aim 2). Lastly, we will evaluate if combination therapy with the most efficacious BET inhibitor preparation from Aim 2 and a CSF1R inhibitor targeting the CSF1R/PU.1 axis is more efficacious against the development and growth of bone metastasis when compared to either agent alone (Aims 3 and 4A- B). Findings could have a major impact on treatment, quality of life, and survival of bone metastasis patients.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$228 )
2024	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	000	5	3/13/2024	NON-COMPETING CONTINUATION	-$228
														Subtotal = -$228

Issue Date FY: 2022 ( Subtotal = $126,738 )
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	000	5	7/25/2022	NON-COMPETING CONTINUATION	$126,738
														Subtotal = $126,738

Issue Date FY: 2021 ( Subtotal = $126,738 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	000	4	7/28/2021	NON-COMPETING CONTINUATION	$126,738
														Subtotal = $126,738

Issue Date FY: 2020 ( Subtotal = $126,738 )
2020	2020	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	003	3	7/15/2020	NON-COMPETING CONTINUATION	$126,738
2020	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	002	2	1/9/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$11,371
2020	2018	MEDICAL UNIVERSITY OF SOUTH CAROLINA THE	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Research Infrastructure Programs	001	1	1/9/2020	NEW	-$11,371
2020	2018	MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Research Infrastructure Programs	000	1	12/10/2019	NEW	$0
														Subtotal = $126,738

Issue Date FY: 2019 ( Subtotal = $126,738 )
2019	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Research Infrastructure Programs	000	2	8/15/2019	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$126,738
														Subtotal = $126,738

Issue Date FY: 2018 ( Subtotal = $126,738 )
2018	2018	MEDICAL UNIVERSITY OF SOUTH CAROLINA	179 ASHLEY AVE	CHARLESTON	SC	29425	CHARLESTON	USA	Research Infrastructure Programs	000	1	8/7/2018	NEW	$126,738
														Subtotal = $126,738

Grand Total All Awards = $633,462

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Macrophage and osteoclast specific targeting for the prevention and treatment of breast cancer bone metastasis

Award Number: K01OD026527

ORGANIZATION: OFFICE OF THE DIRECTOR, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 08/07/2018

PERIOD OF PERFORMANCE END DATE: 07/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer